[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![mupdatesbyscanx Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1926935883384553472.png) Market Updates by ScanX [@mupdatesbyscanx](/creator/twitter/mupdatesbyscanx) on x XXX followers
Created: 2025-07-15 00:35:52 UTC

Sun Pharmaceutical (SUNPHARMA)
on NSE: 1682.60 (+0.63%)

Sun Pharma Settles Litigation with Incyte and Launches LEQSELVI™ for Severe Alopecia Areata in US

View: Positive

Sun Pharmaceutical Industries Limited has reached a settlement with Incyte Corporation regarding LEQSELVI™ (deuruxolitinib), resolving ongoing litigation. The agreement grants Sun Pharma a limited, non-exclusive license for oral deuruxolitinib in specific non-hematology-oncology indications, including alopecia areata, in the US. Sun Pharma has launched LEQSELVI™ in the US for treating adults with severe alopecia areata. The drug showed significant results in clinical trials, with one-third of patients regaining almost all hair by Week XX. Sun Pharma introduced the LEQSELVI SUPPORT™ Program, offering eligible patients medication for as little as $X for up to two years.

Read more:

#Stocks #Market #SUNPHARMA

![](https://pbs.twimg.com/media/Gv29WHEW0AE4ITd.jpg)

XX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1944918804200611869/c:line.svg)

**Related Topics**
[nse](/topic/nse)
[$sunpharmans](/topic/$sunpharmans)

[Post Link](https://x.com/mupdatesbyscanx/status/1944918804200611869)